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whom 274 (28.1%) died. ECMO was performed in 259 pa-
tients, of whom 81 (31.3%) died. One hundred and forty-five 
patients (14.9%) underwent FETO, and from those 76 pa-
tients (52.4%) survived. Survival differed significantly be-
tween years (p = 0.006) and between the 4 centres ( p < 
0.001). In the multivariable logistic regression analysis, lung-
to-head ratio, gestational age at birth, ECMO, centre of birth, 
and year of birth were significantly associated with survival, 
whereas FETO was not.  Conclusions:  The patient popula-
tions were different between centres, which influenced out-
comes. There was a significant variability in survival over 
time and between centres, which should be taken into con-
sideration in the planning of future trials. 
 © 2017 S. Karger AG, Basel 
 Introduction 
 Congenital diaphragmatic hernia (CDH) is a severe 
congenital anomaly with a high outcome variability  [1] . 
Over the last decade, new strategies have been introduced 
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 Abstract 
 Background:  Congenital diaphragmatic hernia (CDH) is a se-
vere congenital anomaly with significant mortality.  Objec-
tives: The aim of this study was to determine if there were 
trends in survival over the last decade and to compare pa-
tient populations, treatment options, and survival rates be-
tween 4 high-volume centres, and hence determine which 
factors were associated with survival.  Methods:  In 4 high-
volume CDH centres from the CDH EURO Consortium,  data 
from all CDH patients born between 2004 and 2013 were 
analysed. The predictive value of variables known at birth 
and the influence of centre-specific treatments (extracorpo-
real membrane oxygenation, ECMO, and foetoscopic endo-
tracheal occlusion, FETO) on survival were evaluated in mul-
tivariable logistic regression analyses.  Results:  Nine hundred 
and seventy-five patients were included in the analysis, of 
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to evaluate and manage CDH patients. It is likely that sur-
vival may have improved over that time, and an aim of 
our study was to test this hypothesis. 
 Patient characteristics, such as foetal liver position (in-
tra-abdominal or intrathoracic)  [2] , stomach position  [3] , 
lung-to-head ratio (LHR)  [4] , observed-to-expected LHR 
 [5] , and the diaphragmatic defect size  [6] can influence 
outcome as well as treatment in a high- or low-volume 
centre. There are differences in opinion about whether ex-
tracorporeal membrane oxygenation (ECMO) improves 
survival as no specific trials have been conducted with the 
primary aim of evaluating the role of ECMO specifically 
for high-risk CDH patients  [7, 8] . The UK ECMO ran-
domised trial investigated the role of ECMO for neonates, 
but only 19% of those included had CDH and there was 
no significant difference in that subgroup with regard to 
survival  [9] . In a multicentre, randomised clinical trial 
(RCT) of the initial ventilation strategy, in which centres 
with and without ECMO availability were included, no 
difference in survival between centres was observed  [10] . 
Many CDH centres chose not to use ECMO because of the 
perceived poor outcome of CDH infants requiring ECMO 
 [11] . Therefore, an important question is whether or not 
ECMO influences survival? In the most severe, prenatally 
detected CDH cases, foetoscopic endotracheal occlusion 
(FETO) may improve outcome  [12, 13] . To date, however, 
the results of only 1 small RCT have been reported. In an 
RCT of 20 severe CDH patients of FETO versus postnatal 
management, survival was significantly better in the FETO 
group  [14] . Thus, it is important to further determine the 
influence of FETO on survival, with the results of the so-
called TOTAL trial due to become available in 2018. By 
analysing the results of 4 high-volume CDH centres, our 
further aim, therefore, was to compare patient popula-
tions, treatment options, and survival rates to determine 
which factors were associated with survival.
 Patients and Methods 
 An observational cohort study was performed involving all pa-
tients with CDH who were born between January 2004 and De-
cember 2013 and treated in 4 high-volume centres of the CDH 
EURO Consortium. The 4 centres were in Rotterdam, London, 
Mannheim, and Rome. From 2008, all patients were treated ac-
cording to a standardised treatment protocol  [15] . The stan-
dardised treatment included immediate intubation after birth, 
permissive hypercapnia, initial ventilation by high-frequency os-
cillation or conventional mechanical ventilation, surgical repair of 
the defect after physiological stabilisation, no routine chest tube 
placement, and no routine use of paralysis. ECMO was only used 
routinely in some centres. In Rotterdam and Mannheim, ECMO 
therapy was available during the whole inclusion period, in Rome, 
ECMO was available in 2013 only, and in London infants could be 
transferred to an ECMO centre. FETO was available in the 4 cen-
tres on a compassionate basis. 
 The ECMO criteria were: an inability to maintain preductal 
saturations >85% or postductal saturations >70%; a high PaCO 2 
with a respiratory acidosis (pH <7.15) despite the optimisation of 
ventilatory management (peak inspiratory pressure >28 cm H 2 O 
or mean airway pressure >17 cm H 2 O to achieve saturation >85%, 
inadequate oxygen delivery with a metabolic acidosis, lactate level 
>5 mmol/L, and pH <7.15); systemic hypotension, resistant to flu-
id and inotropic therapy, resulting in urine output <0.5 mL/kg/h 
for at least 12–24 h, and oxygenation index (mean airway pressure 
× FiO 2 × 100/PaO 2 )  ≥ 40. In Mannheim before 2008, the ECMO 
criteria included an oxygenation index >35 for 0.5–6 h and a pH 
<7.25. In London, FETO therapy was only offered within the con-
text of research trials (NCT01240057) from 2013 onwards, and 
before 2010 as compassionate use. The inclusion criteria for FETO 
were: isolated left-sided CDH and severe pulmonary hypoplasia, 
defined as observed-to-expected LHR <25% as measured prior to 
29 weeks + 6 days, irrespective of the liver position. As the subjects 
were not being submitted to any handling and rules of human be-
haviour were not being imposed, institutional review board ap-
proval was waived.
 Patient demographics and management strategies, including 
prenatal diagnosis, LHR, FETO, gestational age, birth weight, gen-
der, side of the defect, liver position (intrathoracic or intra-abdom-
inal determined during surgical repair), type of repair (primary 
closure or patch repair), age at surgical repair, ECMO, ventilation 
days in survivors, inhaled nitric oxide, and survival were collected 
from the medical records. Death during the first year after birth 
was determined.
 Analysis  
 To determine whether differences in the demographics of the 
infants in the 4 centres were statistically significant, χ 2 tests for cat-
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 Fig. 1. Survival of CDH by centre over the years. The solid black 
line represents Rotterdam, solid grey line represents London, 
dashed black line represents Mannheim, and dashed grey line rep-
resents Rome. 
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egorical data or Kruskal-Wallis tests for continuous data were 
used. Mann-Whitney U tests for continuous data and χ 2 tests for 
categorical data were applied to compare the centre of birth and 
patient characteristics that were known at birth between survivors 
and non-survivors. In these univariate comparisons, the year of 
birth was treated as a categorical variable. Associations between 
prenatal diagnosis, LHR, FETO, gestational age, gender, side of the 
defect, ECMO, centre, and year of birth as independent variables 
and survival were determined using multivariable logistic regres-
sion analysis. The goodness-of-fit of the logistic regression model 
was assessed using the Hosmer-Lemeshow test. Analyses were per-
formed using SPSS 22.0 for Windows (SPSS Inc., Chicago, IL, 
USA). 
 Results 
 During the study period, there were a total of 975 CDH 
patients, of whom 274 (28.1%) died. A prenatal diagnosis 
was made in 820 (84.1%) patients. Overall, there was a 
significant difference in survival over time ( p = 0.006; 
 Fig. 1 ). The survival rate differed from 29 to 97% over the 
years and between the centres. 
 Prenatal diagnosis, LHR, FETO, gestational age, birth 
weight, gender, liver position at surgical repair, type of 
repair, age at surgical repair, ECMO, ventilation days in 
survivors, use of inhaled nitric oxide, and survival were 
significantly different between the 4 centres ( Table  1 ). 
Survivors significantly less often had a prenatal diagnosis, 
had higher LHRs and gestational ages, and a greater pro-
portion had a left-sided defect than non-survivors ( Ta-
ble 2 ). 
 There were also significant differences in survival re-
garding the year of birth and centre of birth ( Table 2 ). In 
Mannheim, 196 patients (41.8%) received ECMO and 
153 (78.1%) of the ECMO-treated patients survived. In 
Rotterdam, 62 patients (31.8%) received ECMO and 25 
(40.3%) of these survived. ECMO-treated patients in Rot-
terdam had lower LHRs and more often had a patch 
repair compared to the ECMO-treated patients in 
 Table 1.  Background characteristics by centre
Rotterdam
(n = 195)
London
(n = 127)
Mannheim
(n = 469)
Rome
(n = 184)
p value
Prenatal diagnosis 139 (71.3) 125 (98.4) 407 (86.8) 149 (81.0) <0.001
LHR 1.47 (1.00 – 1.99) 1.65 (1.33 – 2.20) 1.60 (1.25 – 1.99) 1.82 (1.44 – 2.55) <0.001
FETO
Missing
9 (4.6)
0 (0)
84 (66.1)
0 (0)
48 (10.2)
108 (23.0)
4 (2.2)
0 (0)
<0.001
Gestational age, weeks 38.3 (37.1 – 39.1) 35.7 (33.7 – 38.6) 37.6 (36.1 – 38.4) 38.0 (37.0 – 39.0) <0.001
Premature born 41 (21.0%) 76 (59.8) 153 (32.6) 28 (15.2) <0.001
Birth weight, g 3,000 (2,598 – 3,239) 3,200 (2,345 – 3,600) 2,870 (2,480 – 3,210) 2,930 (2,600 – 3,230) 0.004
Male gender 113 (57.9) 58 (45.7) 274 (58.4) 112 (60.9) 0.04
Side of the defect 0.11
Left
Right
Bilateral
Missing
164 (84.1)
31 (15.9)
0 (0)
0 (0)
115 (90.6)
12 (9.4)
0 (0)
0 (0)
381 (81.2)
83 (17.7)
3 (0.6)
2 (0.4)
151 (82.1)
30 (16.3)
3 (1.6)
0 (0)
Liver position: intrathoracic 70 (40.2) 48 (54.5) 237 (58.5) 48 (36.9) <0.001
Type of repair <0.001
Primary closure
Patch repair
No repair
Missing
42 (21.5)
132 (67.7)
21 (10.8)
0 (0)
38 (43.2)
50 (56.8)
39 (30.7)
0 (0)
88 (18.8)
306 (65.2)
64 (13.6)
11 (2.3)
89 (48.4)
41 (22.3)
54 (29.3)
0 (0)
Age at surgical repair, days 4.0 (3.0 – 6.0) 5.0 (3.0 – 7.0) 6.0 (3.0 – 12.0) 3.0 (2.0 –4.0) <0.001
ECMO 62 (31.8) 0 (0) 196 (41.8) 1 (0.5) 0.01
Ventilation in survivors, days 9.8 (6.0 – 20.1) 13.0 (9.0 – 18.0) 21.3 (11.0 – 30.1) 9.0 (6.0 – 15.0) <0.001
iNO 105 (53.8) 68 (53.5) 266 (56.7) 79 (43.2) <0.001
Survival 142 (72.8) 75 (59.1) 370 (78.9) 114 (62.0) <0.001
 Data are presented as n (%) or median (IQR). Liver position was determined at surgical repair. LHR, lung-to-head ratio; FETO, foe-
toscopic tracheal occlusion; ECMO, extracorporeal membrane oxygenation; iNO, inhaled nitric oxide. 
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Mannheim. In Rome in 2013, 1 patient received ECMO 
and died. None of the patients from London received 
ECMO. ECMO use between the survivors and non-sur-
vivors was not statistically significant. FETO was signifi-
cantly more often used in non-survivors (25.2%) than in 
patients who survived (12.5%).
 In the multivariable logistic regression analysis, a low-
er LHR, lower gestational age, ECMO, centre of birth, and 
year of birth were significantly associated with death ( Ta-
ble 3 ). FETO was not significantly associated with death. 
The  p value of the Hosmer-Lemeshow test was larger than 
0.05, indicating an adequate model calibration. 
 Discussion 
 We have demonstrated variability in survival across a 
10-year period and between 4 high-volume CDH centres. 
In addition, we have highlighted that the patient popula-
tions differed significantly between the centres and this 
influenced outcome. The survival rate was very different 
each year ( Fig. 1 ). 
 In the univariate analysis, we did not find a signifi-
cant difference in ECMO use between the survivors and 
non-survivors. In the multivariable analysis with correc-
tion for patient characteristics, however, we found that 
ECMO was significantly associated with death. This 
may be explained by the fact that only the most severe 
CDH cases received ECMO. The frequency of use of 
ECMO and the outcomes was different between centres. 
In Mannheim, 42% of the patients received ECMO and 
78% of them survived, whereas in Rotterdam 32% of the 
patients received ECMO and only 41% of them survived. 
ECMO-treated patients in Rotterdam, however, had 
lower LHRs and more often had a patch repair, suggest-
ing they were in a more severe category. To identify for 
which subgroup of CDH patients ECMO might be most 
beneficial, predictive postnatal clinical models, such as 
the Score for Neonatal Acute Physiology II  [16] or the 
clinical prediction score published by Brindle et al.  [17] , 
may be useful. 
 Table 2.  Background characteristics for survivors and non-survi-
vors
Survivors
(n = 701)
Non-survivors
(n = 274)
p value
Prenatal diagnosis 570 (81.4) 250 (85.0) <0.001
LHR 1.73 (1.40 – 2.20) 1.35 (1.00 – 1.73) <0.001
FETO
Missing
76 (12.5)
92 (13.1)
69 (25.2)
16 (5.8)
<0.001
Gestational age,
weeks 38.0 (37.0 – 38.9) 37.0 (35.0 – 38.0) <0.001
Gender 0.50
Male
Female
405 (57.8)
295 (42.1)
152 (55.5)
122 (44.5)
Side of the defect 0.02
Left
Right
Bilateral
Missing
595 (84.9)
103 (14.7)
2 (0.3)
1 (0.1)
216 (78.8)
53 (19.3)
4 (1.5)
1 (0.4)
ECMO 178 (25.4) 81 (29.6) 0.20
Centre <0.001
Rotterdam
London
Mannheim
Rome
142 (20.3)
75 (10.7)
370 (52.9)
114 (16.3)
53 (19.3)
52 (19.0)
99 (36.1)
70 (25.5)
Year of birth 0.01
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
51 (58.6)
69 (78.4)
67 (63.2)
58 (67.4)
91 (81.2)
74 (67.9)
86 (75.4)
76 (71.7)
68 (75.6)
61 (79.2)
36 (41.4)
19 (21.6)
39 (36.8)
28 (32.6)
21 (18.8)
35 (32.1)
28 (24.6)
30 (28.3)
22 (24.4)
16 (20.8)
 Data are presented as n (%) or mean ± SD. Numbers do not 
always add up to the total number of the group because of missing 
data. LHR, lung-to-head ratio; FETO, foetoscopic tracheal occlu-
sion; ECMO, extracorporeal membrane oxygenation. 
 Table 3.  Multivariable logistic regression analysis for survival of 
CDH patients
Variable OR 95% CI p value
LHR 4.30 2.98 – 6.21 <0.001
FETO 0.67 0.36 – 1.26 0.21
Gestational age, weeks 1.22 1.10 – 1.35 <0.001
Male gender 0.87 0.59 – 1.29 0.87
Side of the defect 0.39
Left
Bilateral
Right
Ref.
0.32
1.27
0.04 – 2.68
0.73 – 2.20
0.29
0.40
ECMO 0.49 0.30 – 0.81 0.005
Centre <0.001
London
Rotterdam
Rome
Mannheim
Ref.
1.70
0.35
3.39
0.73 – 3.95
0.15 – 0.79
1.61 – 7.14
0.22
0.01
0.001
Year of birth 1.09 1.01 – 1.17 0.03
 LHR, lung-to-head ratio; FETO; foetoscopic tracheal occlu-
sion; ECMO, extracorporeal membrane oxygenation; OR, odds ra-
tio; 95% CI, 95% confidence interval; Ref., reference category.
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 FETO was significantly more often used in non-survi-
vors, likely reflecting the selection criteria for compas-
sionate use. Because FETO was only used on a compas-
sionate basis, it precludes any meaningful conclusion 
with regards to its influence on survival. The TOTAL tri-
al  [18] will hopefully give a definitive answer regarding 
the benefit of FETO for patients with severe CDH. 
 High-volume CDH centres have more experience in 
treating CDH infants than low-volume centres and better 
outcomes  [19] . Nevertheless, the patient characteristics 
were very different between the 4 high-volume centres 
and, despite correction for patient characteristics in the 
multivariable analysis, the centre significantly influenced 
survival. This emphasises the need for correction for cen-
tre in analyses of future multicentre studies on CDH. 
Moreover, long-term follow-up programs on these pa-
tients are essential to assess the quality of life.  
 Our study has many strengths and some limitations. 
We examined the outcome of a large sample ( n = 975) 
over 10 years in 4 high-volume centres. Despite all centres 
agreeing on the use of a consistent protocol during the 
study period, we cannot rule out the possibility that dif-
ferences in physicians, nursing staff, and training may 
have influenced our results. This needs to be taken into 
account in future RCTs. 
 Conclusion 
 We demonstrated variability in the survival of CDH 
patients over time and between centres. Such differences 
need to be taken into account when planning future trials.
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